✦ LIBER ✦

Realize the advance in HCV treatment, but remain cautious

✍ Scribed by Tarik Asselah

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1167 PRE-TREATMENT IP-10 LEVELS AND IL28

✍ Vijgen, L.; Talloen, W.; Scholliers, A.; Johansson, S.; Tuefferd, M.; De Meyer, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Antiviral drug advances in the treatment

✍ Wegzyn, Colleen M; Wyles, David L 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 261 KB

T-29 Predictors of virologic response wi

✍ P. Andreone; T. Berg; S. Pol; S. Roberts; Z. Younossi; M. Diago; E.J. Lawitz; R. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Undetectable HCV-RNA at treatment-week 8

✍ Bruno, S.; Bollani, S.; Zignego, A. L.; Pascasio, J. M.; Magni, C.; Ciancio, A.; 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB

T-27 Efficacy and safety of telaprevir-b

✍ P. Andreone; S. Pol; S. Roberts; Z. Younossi; M. Diago; E.J. Lawitz; R. Focaccia 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 62 KB

OC-13 ADVANCE study: Final results of th

✍ M. Rizzetto; P. Andreone; M. Colombo; A. Scuteri; A. Ciancio; A. Smedile; N. Add 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 48 KB